secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001628280-25-022400
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed
--------------------------------------------------------------------------------

- Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.
- Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.
- Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).
- FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.
- Entered distribution agreement for XCELL PRP system; added new senior leaders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/0001628280-25-022400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025022400/bvs-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer